EchoGo Pro

Outcomes-based AI system that predicts coronary artery disease.
Information source: Vendor
Last updated: Nov. 24, 2021

General Information

Product name EchoGo Pro
Company Ultromics
Subspeciality Cardiac
Modality Ultrasound
Disease targeted Coronary Artery Disease
Key-features Risk prediction, automated segmentation
Suggested use During: interactive decision support (shows abnormalities/results only on demand), report suggestion
After: diagnosis verification

Technical Specifications

Data characteristics
Population All stress echo indications in adults
Input Stress Echo
Input format DICOM
Output PDF Report with key quantification and findings
Output format PDF
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis Automatically, right after the image acquisition
Processing time 10 - 60 seconds


Certified, Class I , MDD
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE) 5.1. Intended Use Based on an echocardiogram, indicate whether there is evidence of disease as an aid to diagnosis. 5.2. Indication for Use EchoGo Pro v1.0.6 is a machine learning-based decision support system, indicated as an adjunct to diagnostic stress echocardiography for patients undergoing assessment for coronary artery disease (CAD). When utilized by an interpreting physician, this device provides information that may be useful in rendering an accurate diagnosis. Patient management decisions should not be made solely on the results of the EchoGo Pro v1.0.6 analysis. EchoGo Pro v1.0.6 is to be used with stress echo exam protocols that contain A2C, A4C and mid[1]ventricular short-axis views at rest and at peak stress. EchoGo Pro v1.0.6 is not intended for the assessment of mild or moderate myocardial ischemia, localization of coronary artery disease, for the assessment of myocardial perfusion, myocardial viability, or valve disease.


Market presence
On market since 03-2020
Distribution channels Caption Health
Countries present (clinical, non-research use) 2
Paying clinical customers (institutes) 1
Research/test users (institutes) 2
Pricing model Pay-per-use, Subscription
Based on Number of analyses


Peer reviewed papers on performance
Non-peer reviewed papers on performance

  • Automated Coronary Artery Disease Prediction (read)

Other relevant papers